Skip to main content
Premium Trial:

Request an Annual Quote

Sirigen Raises $6.1M for Technology Commercialization

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK amplification firm Sirigen today announced it has raised about £3.8 million ($6.1 million) in two completed rounds of financing, which it will use to support commercialization of its High Sensitivity Fluorescence technology.

Leading the rounds was a syndicate of new investors including IQ Capital, the National Endowment for Science, Technology, and the Arts, and YFM Private Equity. Existing investors Seraphim Capital and Oxford Capital Partners also participated.

According to Sirigen's website, its HSF technology overcomes fluorescent detection's dependence on the performance of reporter dyes that are used and their ability to absorb excitation light. The HSF polymers are designed "for maximal absorption of exciting light and conversion to fluorescent signal."

The firm said that its technology can be used in a wide range of assay formats and applications including multiplex and molecular diagnostics, microarrays, and DNA sequencing.

The company also announced that Ivan Griffin at NESTA and Max Bautin at IQ Capital have been appointed investor directors at Sirigen. David Evans was appointed chairman of the board and Arthur Cole was appointed as a non-executive director.

Evans is the former CFO of Shield Diagnostics and is chairman and non-executive director at a number of diagnostic and life science companies. He also was chairman of DxS, a molecular diagnostic firm acquired by Qiagen last year.

Cole was executive vice president of Visible Genetics and vice president of new business development at Pharmacia Biotech.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.